The ABCA1 agonist CS6253 shows favorable safety and pharmacokinetics in IND‐enabling toxicology and Phase 1 human studies aimed at the indication of Alzheimer’s disease

Jan O Johansson, Bengt Winblad, Daniel M Michaelson, Henrik Zetterberg, Jeffrey L Cummings, Hussein N Yassine · 2025

Read The ABCA1 agonist CS6253 shows favorable safety and pharmacokinetics in IND‐enabling toxicology and Phase 1 human studies aimed at the indication of Alzheimer’s disease by Jan O Johansson, Bengt Winblad, Daniel M Michaelson, Henrik Zetterberg, Jeffrey L Cummings, Hussein N Yassine (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712598.txt.

Description

Jan Johansson and five co-authors report in 2025 safety tests for a new drug aimed at Alzheimer disease in people with a risky gene form. The drug, CS6253, boosts a transport protein that moves cholesterol in the brain. Older ways to raise that protein stir liver side effects.

The drug is built from a tail piece of a brain fat carrier and firms up the transport protein directly. Safety studies in rats and monkeys clear the way for human trials. A first human study then tests single and repeated doses against placebo. Early results show sound safety and drug levels in the body. Mouse work hints at brain and blood vessel gains worth probing further.

Catalog record

CREATORJan O Johansson, Bengt Winblad, Daniel M Michaelson, Henrik Zetterberg, Jeffrey L Cummings, Hussein N Yassine
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712598

Browse the full library · About the Tower of Babel